Trial · NCT07902297
Effects of Perturbation-Based Versus Conventional Balance Training on Reactive Stepping Ability in Patients With Diabetic Peripheral Neuropathy
NCT07902297, Not applicable, Recruiting, Lahore University of Biological and Applied Sciences
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Perturbation-Based Versus Conventional Balance Training on Reactive Stepping Ability in Patients With Diabetic Peripheral Neuropathy. Trials, record NCT07902297. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07902297
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Perturbation-Based Versus Conventional Balance Training on Reactive Stepping Ability in Patients With Diabetic Peripheral Neuropathy
- NCT number
- NCT07902297
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Lahore University of Biological and Applied Sciences
- Conditions
- Diabetic Peripheral Neuropathy
- Interventions
- Perturbation-Based Balance Training (PBBT), Conventional Balance Training (CBT)
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Reactive stepping ability (Lean-and-Release Test) | Baseline (Week 0), post-intervention (Week 8), and follow-up (Week 12) | The Lean-and-Release Test (LRT) will be used to assess reactive stepping ability. Participants stand barefoot in a standardized position and lean forward while the assessor supports them at the waist, bearing approximately 8-12% of their estimated body weight. The assessor then suddenly withdraws support, creating an unexpected forward perturbation that requires a rapid compensatory step. Each session consists of one unscored familiarization trial followed by 13 test trials (10 released trials and 3 false trials). The primary outcome is the proportion of successful single-step recovery trials out of the 10 released trials, with a higher proportion indicating better reactive stepping performance. The mean number of recovery steps across the 10 released trials will also be recorded, with a lower mean indicating greater reactive stepping efficiency. |
| Secondary | Dynamic balance (Mini-BESTest) | Baseline (Week 0), post-intervention (Week 8), and follow-up (Week 12) | The Mini-Balance Evaluation Systems Test (Mini-BESTest) assesses reactive postural control, anticipatory postural adjustments, sensory orientation, and dynamic gait stability. It has 14 items, each scored 0 to 2, with a maximum score of 28. Higher scores indicate better balance performance and lower fall risk, and a score below 20 commonly indicates increased fall risk. |
| Secondary | Functional balance (Berg Balance Scale) | Baseline (Week 0), post-intervention (Week 8), and follow-up (Week 12) | The Berg Balance Scale (BBS) assesses static and anticipatory balance during functional tasks such as standing, turning, reaching, and transferring. It has 14 items, each scored 0 to 4, with a maximum score of 56. Higher scores indicate better functional balance, and scores below 45 suggest increased fall risk. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07902297
GET https://conductscience.org/api/trials/v1/NCT07902297/registered